Across TCGA pan-cancer cohorts, IGLV3-22 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGLV3-22 data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher IGLV3-22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGLV3-22 expression acts as an unfavorable survival marker.

COAD, LGG, and SKCM are the cancer types where IGLV3-22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.140	0.806	<.001	30	view →
LGG	OS	Median	All	0.147	0.811	<.001	12	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGLV3-22 tumor-vs-normal RNA expression · all IGLV3-22 data types